Analyzing Biotherapeutics

Biotherapeutics are currently the fastest growing class of therapeutics in the country, accounting for over 50% of new drug approvals this year. One of the major challenges in this sector continues to be development of robust quality control techniques for ensuring the safety and efficacy of these drugs. Our work seeks to capture the unfolding features of biotherapeutics, and link them to therapeutically-relevant differences in their structures; ultimately building high-throughput methods to rapidly analyze novel therapeutic proteins.

CIU helps distinguish between different antibodies.

For more details, please refer to Tian, Y., et al. Anal. Chem., 2015, 87 (22).

For a detailed summary of current work in this research area, please visit the publication site.